164 related articles for article (PubMed ID: 35327957)
1. Breast Tumour Kinase (Brk/PTK6) Contributes to Breast Tumour Xenograft Growth and Modulates Chemotherapeutic Responses In Vitro.
Burmi RS; Box GM; Wazir U; Hussain HA; Davies JA; Court WJ; Eccles SA; Jiang WG; Mokbel K; Harvey AJ
Genes (Basel); 2022 Feb; 13(3):. PubMed ID: 35327957
[TBL] [Abstract][Full Text] [Related]
2. Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
Regan Anderson TM; Ma S; Perez Kerkvliet C; Peng Y; Helle TM; Krutilina RI; Raj GV; Cidlowski JA; Ostrander JH; Schwertfeger KL; Seagroves TN; Lange CA
Mol Cancer Res; 2018 Nov; 16(11):1761-1772. PubMed ID: 29991529
[TBL] [Abstract][Full Text] [Related]
3. Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer.
Regan Anderson TM; Ma SH; Raj GV; Cidlowski JA; Helle TM; Knutson TP; Krutilina RI; Seagroves TN; Lange CA
Cancer Res; 2016 Mar; 76(6):1653-63. PubMed ID: 26825173
[TBL] [Abstract][Full Text] [Related]
4. Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.
Lofgren KA; Ostrander JH; Housa D; Hubbard GK; Locatelli A; Bliss RL; Schwertfeger KL; Lange CA
Breast Cancer Res; 2011 Sep; 13(5):R89. PubMed ID: 21923922
[TBL] [Abstract][Full Text] [Related]
5. Breast Tumor Kinase (Brk/PTK6) Mediates Advanced Cancer Phenotypes via SH2-Domain Dependent Activation of RhoA and Aryl Hydrocarbon Receptor (AhR) Signaling.
Dwyer AR; Kerkvliet CP; Krutilina RI; Playa HC; Parke DN; Thomas WA; Smeester BA; Moriarity BS; Seagroves TN; Lange CA
Mol Cancer Res; 2021 Feb; 19(2):329-345. PubMed ID: 33172975
[TBL] [Abstract][Full Text] [Related]
6. Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.
Castro NE; Lange CA
Breast Cancer Res; 2010; 12(4):R60. PubMed ID: 20687930
[TBL] [Abstract][Full Text] [Related]
7. The alternative splice variant of protein tyrosine kinase 6 negatively regulates growth and enhances PTK6-mediated inhibition of β-catenin.
Brauer PM; Zheng Y; Evans MD; Dominguez-Brauer C; Peehl DM; Tyner AL
PLoS One; 2011 Mar; 6(3):e14789. PubMed ID: 21479203
[TBL] [Abstract][Full Text] [Related]
8. Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression.
Regan Anderson TM; Peacock DL; Daniel AR; Hubbard GK; Lofgren KA; Girard BJ; Schörg A; Hoogewijs D; Wenger RH; Seagroves TN; Lange CA
Cancer Res; 2013 Sep; 73(18):5810-20. PubMed ID: 23928995
[TBL] [Abstract][Full Text] [Related]
9. Brk/PTK6 and Involucrin Expression May Predict Breast Cancer Cell Responses to Vitamin D3.
Box C; Pennington C; Hare S; Porter S; Edwards D; Eccles S; Crompton M; Harvey A
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445934
[TBL] [Abstract][Full Text] [Related]
10. Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo.
Falkenberg N; Anastasov N; Höfig I; Bashkueva K; Lindner K; Höfler H; Rosemann M; Aubele M
Mol Oncol; 2015 Jan; 9(1):282-94. PubMed ID: 25241146
[TBL] [Abstract][Full Text] [Related]
11. Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation.
Harvey AJ; Crompton MR
Oncogene; 2003 Aug; 22(32):5006-10. PubMed ID: 12902983
[TBL] [Abstract][Full Text] [Related]
12. BRK confers tamoxifen-resistance in breast cancer via regulation of tyrosine phosphorylation of CDK1.
Mandapati A; Ning Z; Baharani A; Lukong KE
Cell Signal; 2023 Aug; 108():110723. PubMed ID: 37216999
[TBL] [Abstract][Full Text] [Related]
13. Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers.
Qiu L; Levine K; Gajiwala KS; Cronin CN; Nagata A; Johnson E; Kraus M; Tatlock J; Kania R; Foley T; Sun S
PLoS One; 2018; 13(6):e0198374. PubMed ID: 29879184
[TBL] [Abstract][Full Text] [Related]
14. Breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal and neoplastic biliary epithelia.
Mizuguchi Y; Specht S; Isse K; Sasatomi E; Lunz JG; Takizawa T; Demetris AJ
J Hepatol; 2015 Aug; 63(2):399-407. PubMed ID: 25770659
[TBL] [Abstract][Full Text] [Related]
15. Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK.
Brauer PM; Tyner AL
Biochim Biophys Acta; 2010 Aug; 1806(1):66-73. PubMed ID: 20193745
[TBL] [Abstract][Full Text] [Related]
16. Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition.
Ai M; Liang K; Lu Y; Qiu S; Fan Z
Cancer Biol Ther; 2013 Mar; 14(3):237-45. PubMed ID: 23291984
[TBL] [Abstract][Full Text] [Related]
17. Hsp90 rescues PTK6 from proteasomal degradation in breast cancer cells.
Kang SA; Cho HS; Yoon JB; Chung IK; Lee ST
Biochem J; 2012 Oct; 447(2):313-20. PubMed ID: 22849407
[TBL] [Abstract][Full Text] [Related]
18. HIF-1α-independent hypoxia-induced rapid PTK6 stabilization is associated with increased motility and invasion.
Pires IM; Blokland NJ; Broos AW; Poujade FA; Senra JM; Eccles SA; Span PN; Harvey AJ; Hammond EM
Cancer Biol Ther; 2014 Oct; 15(10):1350-7. PubMed ID: 25019382
[TBL] [Abstract][Full Text] [Related]
19. PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
Byerly JH; Port ER; Irie HY
Breast Cancer Res; 2020 Jun; 22(1):72. PubMed ID: 32600444
[TBL] [Abstract][Full Text] [Related]
20. Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.
Jiang J; Gui F; He Z; Li L; Li Y; Li S; Wu X; Deng Z; Sun X; Huang X; Huang W; Han S; Zhang T; Wang Z; Jiao B; Song S; Wang H; Chen L; Zhou D; Liu Q; Ren R; Zhang J; Deng X
Cancer Res; 2017 Jan; 77(1):175-186. PubMed ID: 27758886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
